title: Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.
abstract: EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with essential thrombocythemia (ET) were recruited across 13 European countries. We report patient characteristics and cytoreductive treatment patterns of ET across Europe. Hydroxycarbamide (HC; 64.3%) and anagrelide (22.0%) were the two main cytoreductive treatments prescribed. The proportions of patients taking either HC or anagrelide varied across countries, as did the number of patients receiving anti-aggregatory therapy in addition to cytoreductive treatment. This real-world evidence demonstrates that, generally, treatment patterns of ET across Europe adhere to expert recommendations, with some notable variations between countries.
authors.affiliation: Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain. 92717@imas.imim.es
authors.forename: Carlos
authors.initials: C
authors.lastname: Besses
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Kiladjian
authors.forename: Martin
authors.initials: M
authors.lastname: Griesshammer
authors.forename: Luigi
authors.initials: L
authors.lastname: Gugliotta
authors.forename: Claire
authors.initials: C
authors.lastname: Harrison
authors.forename: Ruth
authors.initials: R
authors.lastname: Coll
authors.forename: Jonathan
authors.initials: J
authors.lastname: Smith
authors.forename: Brihad
authors.initials: B
authors.lastname: Abhyankar
authors.forename: Gunnar
authors.initials: G
authors.lastname: Birgegård
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide